Trial of ABI-007 Administered Weekly in Chemotherapy Naive Patients With Advanced Non-Small Cell Lung Cancer
NCT00073723
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
75
Enrollment
INDUSTRY
Sponsor class
Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG:
ABI-007
Sponsor
Celgene Corporation